Genprex (GNPX) Financials

Genprex’s financials continue to show a pre-revenue biotech model with meaningful cash burn, but the company also had a stronger cash position at the end of Q1 2026 than it did a year earlier. Over the last several years, Genprex has not generated operating revenue, so its results have been driven by research and development spending, general and administrative costs, and repeated equity financing.

What stands out most is the company’s ability to raise cash when needed. In Q1 2026, Genprex ended the quarter with $18.0 million in cash and equivalents, up sharply from $3.5 million at the end of Q1 2025 and $1.1 million at the end of Q3 2025. That gives the company more near-term flexibility, even though operations are still losing money.

• Cash balance improved significantly: Cash and equivalents rose to $18.0 million in Q1 2026, providing a much larger cushion than in prior quarters.
• Financing provided major support: The company raised $13.4 million from common equity issuance in Q1 2026, helping offset operating losses.
• Operating cash burn moderated year over year: Net cash used in operating activities was $3.1 million in Q1 2026, better than the $4.2 million used in Q1 2025 and the $4.1 million used in Q4 2025.
• R&D spending is still being maintained: Research and development expense was $2.7 million in Q1 2026, showing continued investment in the pipeline.
• No revenue reported: Genprex again reported $0 in revenue, so the company remains entirely dependent on financing rather than product sales.
• Other income was immaterial: Non-operating income/expense had only a minimal impact in Q1 2026.
• Balance sheet is still equity-heavy: Total equity of $16.9 million was supported by a large common stock balance and accumulated losses in retained earnings.
• Ongoing quarterly losses remain substantial: Genprex reported a Q1 2026 net loss of $4.5 million, only slightly better than recent quarters.
• Operating expenses remain high relative to the company’s size: Total operating expenses were $4.5 million in Q1 2026, driven mainly by R&D and SG&A.
• Historical dilution has been significant: The company has repeatedly issued shares to fund operations, which can pressure per-share value over time.

Looking at the trend over the past four years, Genprex has not shown a path to profitability yet. Quarterly losses have generally stayed in the multi-million-dollar range, with operating expenses often between $3 million and $7 million. The company’s cash balance has also swung widely, reflecting dependence on periodic stock issuance to fund research and overhead.

The balance sheet trend is mixed. Compared with the end of 2024 and early 2025, the Q1 2026 cash position is a clear improvement. However, total liabilities were still $3.4 million at quarter-end, and the business remains exposed to future financing needs if losses continue at the current pace.

Bottom line: Genprex appears to have bought itself more runway with recent equity financing, but the core operating picture remains unchanged: no revenue, recurring losses, and ongoing reliance on the capital markets. For retail investors, this remains a highly speculative biotech story where cash management and financing activity are just as important as clinical progress.